Naphazoline

DRUG3 trials

Sponsors

Bausch & Lomb Incorporated, Sanofi

Conditions

Allergic ConjunctivitisNeoplasm Malignant

Phase 1

Evaluation of SAR408701 in Japanese Patients With Advanced Malignant Solid Tumors

CompletedNCT03324113

SanofiNeoplasm Malignant

Start: 2017-10-17End: 2022-12-26Updated: 2025-08-05

Phase 3

Ketotifen/Naphazoline Ophthalmic Solution in the Conjunctival Allergen Challenge Model of Allergic Conjunctivitis.

CompletedNCT00769886

Bausch & Lomb IncorporatedAllergic Conjunctivitis

Start: 2008-10-31End: 2009-06-30Updated: 2024-04-03

Ketotifen/Naphazoline Ophthalmic Solution in the Conjunctival Allergen Challenge Model of Acute Allergic Conjunctivitis.

CompletedNCT00770133

Bausch & Lomb IncorporatedAllergic Conjunctivitis

Start: 2010-02-28End: 2010-06-30Updated: 2020-10-27